Dear Colleague Letter: FEM-PrEP Clinical Trial examining Pre-Exposure Prophylaxis (PrEP) for HIV prevention among heterosexual women

Today, FHI announced that it will stop the FEM-PrEP study of pre-exposure prophylaxis (PrEP) for HIV prevention among heterosexual women. The decision was made after a regularly scheduled interim review of data by the trial’s independent data monitoring committee determined that the trial could not demonstrate efficacy even if it continued to its originally-planned conclusion.

Source: http://www.cdc.gov/hiv/prep/femprep.htm

HEWLETT PACKARD CO INTERNATIONAL BUSINESS MACHINES CORP (IBM) DELL, INC. MICROSOFT CORP